Opus Genetics launches gene therapy clinical trial for retinitis pigmentosa

Opus Genetics (IRD) announced the launch and funding of its clinical trial evaluating a gene therapy for MERTK-related retinitis pigmentosa. The study is being launched in Abu Dhabi, the capital of the United Arab Emirates in collaboration with the Department of Health – Abu Dhabi, Cleveland Clinic Abu Dhabi, the Innovative Research Oversight and Support division of the M42 group, and the Authority of Social Contribution – Ma’an. The clinical trial will evaluate the safety and efficacy of OPGx-MERTK, an investigational adeno-associated virus-based gene therapy developed by Opus Genetics. The